Neuraxis Inc (NRXS) — Titan Protect Analysis

NRXS

Neuraxis Inc

Healthcare · ·

$6.84

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$86M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-115.92

Based on estimated future earnings — lower means cheaper

Rev Growth

+79.5%

Year-over-year revenue change

Profit Margin

-170.1%

How much profit the company keeps from each dollar of revenue

ROE

-242.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$11.00

+61% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 2 analysts covering this stock

About Neuraxis Inc

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a

https://neuraxis.com

Country: United States Employees: 24 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.849

Good returns relative to risk taken

Kelly Fraction

0.0306

Modest edge detected — smaller position warranted

Calmar Ratio

0.982

Acceptable balance between returns and drawdown risk

Annual Return

50.2%

Historical annualised return based on price data

Max Drawdown

-51.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$9.33

27% below the year high

52W Low

$2.20

211% above the year low

Avg Volume

189,042

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.80

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

6.15

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

85.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-108.3%

Profit from core operations before interest and tax

Free Cash Flow

$-3,496,184

Negative — the business is spending more than it generates

Revenue (TTM)

$4M

Total revenue over the last 12 months

Net Income

$-8,073,756

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$13.00

Target Median

$11.00

Target Low

$9.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go